azacitidine-tablets-300-mg-500x500-removebg-preview

bd-zadine-200mg-tablet-500x500-1-300x300

Anti-Cancer

AZACITIDINE (BD-ZADINE) Tablet

Name: AZACITIDINE (BD-ZADINE) Tablet
Brand: variable
Availability: InStock

$1,890.00

zacitidine BD-ZADINE 200/300 MG Tablet represents a significant therapeutic advance in the management of myelodysplastic syndromes and acute myeloid leukemia, offering targeted therapy that can improve outcomes and quality of life for patients facing these challenging diseases. With careful monitoring, patient education, and access to treatment,

Sku:

N/A

Tag:

AZACITIDINE BD-ZADINE

Description

Azacitidine BD-ZADINE 200/300 MG Tablet stands as a cornerstone in the treatment of certain hematologic malignancies, particularly myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). With its active ingredient, azacitidine, this tablet represents a significant advancement in the management of these challenging diseases, offering renewed hope and improved outcomes for patients facing this diagnosis.

Key Features:

Targeted Therapy: Azacitidine is a nucleoside metabolic inhibitor that functions by incorporating into DNA and RNA, leading to the disruption of DNA methylation and subsequent gene expression. This mechanism of action restores normal hematopoiesis and inhibits the growth of abnormal cells in the bone marrow.
Treatment of MDS and AML: Azacitidine BD-ZADINE Tablet is indicated for the treatment of patients with intermediate- or high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) with 20-30% blasts and multi-lineage dysplasia. It offers a valuable therapeutic option for individuals at various stages of these diseases, improving survival and quality of life.
Multiple Strengths: Available in tablet form with strengths of 200mg and 300mg, Azacitidine BD-ZADINE Tablet allows for personalized dosing tailored to individual patient needs and treatment plans, facilitating optimized therapeutic outcomes.
Oral Administration: Administered orally once daily for 7 consecutive days of a 28-day cycle, Azacitidine BD-ZADINE Tablet is typically taken at the same time each day. Patients should adhere strictly to the prescribed dosing schedule and follow healthcare provider instructions meticulously.
Efficacy: Clinical trials have demonstrated the efficacy of azacitidine in improving overall survival, delaying disease progression, and reducing the risk of transformation to AML in patients with MDS and AML. It has shown superiority over conventional care regimens, offering a survival benefit and improving quality of life.
Side Effects: Common side effects of Azacitidine may include nausea, vomiting, diarrhea, fatigue, anemia, thrombocytopenia, and injection site reactions. Patients should be closely monitored for adverse reactions, and dose adjustments or supportive care measures may be necessary to manage side effects.
Patient Education: Patients should receive comprehensive counseling on proper medication administration, potential side effects, and the importance of adherence to treatment. They should also be educated on the need for regular monitoring and reporting of any concerning symptoms to their healthcare provider.
Consultation with Healthcare Provider: Treatment with Azacitidine BD-ZADINE Tablet should be initiated and monitored by a qualified hematologist or oncologist experienced in the management of MDS and AML. Close collaboration between the patient and healthcare provider is essential throughout the treatment journey.
Access and Affordability: Efforts should be made to ensure access to Azacitidine for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate the financial burden of treatment.

In conclusion, Azacitidine BD-ZADINE 200/300 MG Tablet represents a significant therapeutic advance in the management of myelodysplastic syndromes and acute myeloid leukemia, offering targeted therapy that can improve outcomes and quality of life for patients facing these challenging diseases. With careful monitoring, patient education, and access to treatment, Azacitidine holds promise in reshaping the landscape of hematologic cancer care and providing hope for those affected by these conditions.